Ross S. Francis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ross S. Francis has a total of 315 co-authors. Here are the top co-authors by number of shared publications:
- Robert J. Ellis
Kidney Disease Research Collaborative, Princess Alexandra Hospital and The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia
11 shared publications - David Wayne Johnson
Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia
9 shared publications Christudas Morais
Centre for Kidney Disease Research, University of Queensland Faculty of Medicine, Translational Research Institute, Brisbane, Australia
7 shared publications- Rajiv Khanna
QIMR Berghofer Medical Research Institute
7 shared publications Simon T. Wood
Centre for Kidney Disease Research, University of Queensland Faculty of Medicine, Translational Research Institute, Brisbane, Australia; Department of Urology, Princess Alexandra Hospital, Brisbane, Australia
7 shared publications- Carmel Mary Hawley
Australasian Kidney Trials Network (AKTN), The University of Queensland, Brisbane, Queensland, Australia
6 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (7) , e70247
Rhabdomyolysis After COVID ‐19
We report a case of a kidney transplant recipient who presented with generalised muscle pain, weakness and brown urine discoloration in the setting of acute severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Investigations demonstrated rhabdomyolysis with elevated creatine kinase levels and severe acute kidney injury (AKI). A muscle biopsy was consistent with an immune‐mediated necrotising myositis. The patient received intravenous fluids, remdesivir and haemodialysis, with subsequent resolution of muscle injury and recovery of kidney function. This case indicates the potential for severe myositis to develop in patients with SARS‐CoV‐2 infection with the potential for rhabdomyolysis and AKI to occur.
- 14 July 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (7) , e70247
Open AccessRhabdomyolysis After COVID ‐19
We report a case of a kidney transplant recipient who presented with generalised muscle pain, weakness and brown urine discoloration in the setting of acute severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Investigations demonstrated rhabdomyolysis with elevated creatine kinase levels and severe acute kidney injury (AKI). A muscle biopsy was consistent with an immune‐mediated necrotising myositis. The patient received intravenous fluids, remdesivir and haemodialysis, with subsequent resolution of muscle injury and recovery of kidney function. This case indicates the potential for severe myositis to develop in patients with SARS‐CoV‐2 infection with the potential for rhabdomyolysis and AKI to occur.
- Open Access
- 3 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 78 patients from 19 hospitals across Australia and New Zealand, treated over the last 15 years with “off-the-shelf” allogeneic T cells directed to a combination of Epstein–Barr virus (EBV), cytomegalovirus (CMV), BK polyomavirus (BKV), John Cunningham virus (JCV) and/or adenovirus (AdV) under the Australian Therapeutic Goods Administration’s Special Access Scheme. Most patients had severe post-transplant viral complications, including drug-resistant end-organ CMV disease, BKV-associated haemorrhagic cystitis and EBV-driven post-transplant lymphoproliferative disorder. Adoptive immunotherapy is well tolerated with few adverse effects. Importantly, 46/71 (65%) patients show definitive clinical improvement including reduction in viral load, clinical symptoms and complete resolution of end-organ disease. In addition, seven high-risk patients remain disease free. Based on this long-term encouraging clinical experience, we propose that a dedicated nationally funded centre for anti-viral cellular therapies should be considered to provide T cell therapies for critically ill patients for compassionate use.
- 3 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Open AccessCompassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 78 patients from 19 hospitals across Australia and New Zealand, treated over the last 15 years with “off-the-shelf” allogeneic T cells directed to a combination of Epstein–Barr virus (EBV), cytomegalovirus (CMV), BK polyomavirus (BKV), John Cunningham virus (JCV) and/or adenovirus (AdV) under the Australian Therapeutic Goods Administration’s Special Access Scheme. Most patients had severe post-transplant viral complications, including drug-resistant end-organ CMV disease, BKV-associated haemorrhagic cystitis and EBV-driven post-transplant lymphoproliferative disorder. Adoptive immunotherapy is well tolerated with few adverse effects. Importantly, 46/71 (65%) patients show definitive clinical improvement including reduction in viral load, clinical symptoms and complete resolution of end-organ disease. In addition, seven high-risk patients remain disease free. Based on this long-term encouraging clinical experience, we propose that a dedicated nationally funded centre for anti-viral cellular therapies should be considered to provide T cell therapies for critically ill patients for compassionate use.
- Open Access
- 13 August 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (4) , 504-506
Should Protocol Kidney Biopsies be a Part of Routine Post-Transplant Care? CON
An abstract is unavailable. This article is available as a PDF only.
- 13 August 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (4) , 504-506
Open AccessShould Protocol Kidney Biopsies be a Part of Routine Post-Transplant Care? CON
An abstract is unavailable. This article is available as a PDF only.
- 31 July 2024
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 20 (11) , 707-721
Drug repurposing for glomerular diseases: an underutilized resource
Drug repurposing in glomerular disease can deliver opportunities for steroid-free regimens, enable personalized multi-target options for resistant or relapsing disease and enhance treatment options for understudied populations (for example, children) and in resource-limited settings. Identification of drug-repurposing candidates can be data driven, which utilizes existing data on disease pathobiology, drug features and clinical outcomes, or experimental, which involves high-throughput drug screens. Information from databases of approved drugs, clinical trials and PubMed registries suggests that at least 96 drugs on the market cover 49 targets with immunosuppressive potential that could be candidates for drug repurposing in glomerular disease. Furthermore, evidence to support drug repurposing is available for 191 immune drug target–glomerular disease pairs. Non-immunological drug repurposing includes strategies to reduce haemodynamic overload, podocyte injury and kidney fibrosis. Recommended strategies to expand drug-repurposing capacity in glomerular disease include enriching drug databases with glomeruli-specific information, enhancing the accessibility of primary clinical trial data, biomarker discovery to improve participant selection into clinical trials and improve surrogate outcomes and initiatives to reduce patent, regulatory and organizational hurdles.
- 31 July 2024
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 20 (11) , 707-721
Drug repurposing for glomerular diseases: an underutilized resource
Drug repurposing in glomerular disease can deliver opportunities for steroid-free regimens, enable personalized multi-target options for resistant or relapsing disease and enhance treatment options for understudied populations (for example, children) and in resource-limited settings. Identification of drug-repurposing candidates can be data driven, which utilizes existing data on disease pathobiology, drug features and clinical outcomes, or experimental, which involves high-throughput drug screens. Information from databases of approved drugs, clinical trials and PubMed registries suggests that at least 96 drugs on the market cover 49 targets with immunosuppressive potential that could be candidates for drug repurposing in glomerular disease. Furthermore, evidence to support drug repurposing is available for 191 immune drug target–glomerular disease pairs. Non-immunological drug repurposing includes strategies to reduce haemodynamic overload, podocyte injury and kidney fibrosis. Recommended strategies to expand drug-repurposing capacity in glomerular disease include enriching drug databases with glomeruli-specific information, enhancing the accessibility of primary clinical trial data, biomarker discovery to improve participant selection into clinical trials and improve surrogate outcomes and initiatives to reduce patent, regulatory and organizational hurdles.
- Open Access
- 18 July 2024
- Published by Springer Nature in Research Square
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 75 patients from 15 hospitals across Australia and New Zealand, treated over the last 15 years with “off-the-shelf” allogeneic T-cells directed to a combination of Epstein–Barr virus (EBV), cytomegalovirus (CMV), BK polyomavirus (BKV), John Cunningham virus (JCV) and/or adenovirus (AdV) under the Australian Therapeutic Goods Administration’s Special Access Scheme. Most patients had severe post-transplant viral complications, including drug-resistant end-organ CMV disease, BKV-associated haemorrhagic cystitis and EBV-driven post-transplant lymphoproliferative disorder. Adoptive immunotherapy was well tolerated with few adverse effects. Importantly, 50/75 (66.7%) patients showed definitive clinical improvement including reduction in viral load, clinical symptoms, complete resolution of end-organ disease and remained disease free. Based on this long-term encouraging clinical experience, we propose that a dedicated nationally funded centre for anti-viral cellular therapies should be established to provide T cell therapies for critically ill patients for compassionate use.
- 18 July 2024
- Published by Springer Nature in Research Square
Open AccessCompassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 75 patients from 15 hospitals across Australia and New Zealand, treated over the last 15 years with “off-the-shelf” allogeneic T-cells directed to a combination of Epstein–Barr virus (EBV), cytomegalovirus (CMV), BK polyomavirus (BKV), John Cunningham virus (JCV) and/or adenovirus (AdV) under the Australian Therapeutic Goods Administration’s Special Access Scheme. Most patients had severe post-transplant viral complications, including drug-resistant end-organ CMV disease, BKV-associated haemorrhagic cystitis and EBV-driven post-transplant lymphoproliferative disorder. Adoptive immunotherapy was well tolerated with few adverse effects. Importantly, 50/75 (66.7%) patients showed definitive clinical improvement including reduction in viral load, clinical symptoms, complete resolution of end-organ disease and remained disease free. Based on this long-term encouraging clinical experience, we propose that a dedicated nationally funded centre for anti-viral cellular therapies should be established to provide T cell therapies for critically ill patients for compassionate use.
- Open Access
- 16 October 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9 (11) , e1548
Putting Guidelines Into Practice: Is Frailty Measurement at the Time of Kidney Transplant Eligibility Assessment Valid, Feasible, and Acceptable to Patients?
Background. Clinical Practice Guidelines suggest that frailty be measured during kidney transplant eligibility assessments. Yet it is not known how frailty is best assessed in this setting or whether its assessment is acceptable to patients. We aimed to examine the construct validity and feasibility of Frailty Index (FI) assessment among patients attending a kidney transplant assessment clinic and to explore patients’ perspectives on frailty and the acceptability of its routine assessment. Methods. A 58-item FI was calculated for 147 clinic patients. Semistructured interviews were conducted with a subgroup of 29 patients. The FI was validated against normative FI characteristics (mean, distribution, limit), age, and the Estimated Post-Transplant Survival Score. Feasibility was assessed using descriptive statistics. Qualitative data were analyzed using reflexive thematic analysis. Results. The mean FI was 0.23 (±0.10, normal distribution, limit 0.53). FI increased with age and Estimated Post-Transplant Survival score. The FI was completed for 62.8% of eligible patients (147/234). The median completion time was 10 min, and completion rate (with no missing data) was 100%. Four themes were identified: perceptions of frailty, acceptability, perceived benefits, and risks of frailty measurement. Patients linked frailty with age and adverse outcomes, and most did not consider themselves frail. Patients reported that the FI was quick, simple, and efficient. They felt that frailty assessment is relevant to transplant eligibility and should be used to address potentially reversible factors. Conclusions. The FI demonstrated construct validity and was feasible and acceptable in this clinic setting. The challenge is ensuring that routine assessments lead to better care.
- 16 October 2023
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 9 (11) , e1548
Open AccessPutting Guidelines Into Practice: Is Frailty Measurement at the Time of Kidney Transplant Eligibility Assessment Valid, Feasible, and Acceptable to Patients?
Background. Clinical Practice Guidelines suggest that frailty be measured during kidney transplant eligibility assessments. Yet it is not known how frailty is best assessed in this setting or whether its assessment is acceptable to patients. We aimed to examine the construct validity and feasibility of Frailty Index (FI) assessment among patients attending a kidney transplant assessment clinic and to explore patients’ perspectives on frailty and the acceptability of its routine assessment. Methods. A 58-item FI was calculated for 147 clinic patients. Semistructured interviews were conducted with a subgroup of 29 patients. The FI was validated against normative FI characteristics (mean, distribution, limit), age, and the Estimated Post-Transplant Survival Score. Feasibility was assessed using descriptive statistics. Qualitative data were analyzed using reflexive thematic analysis. Results. The mean FI was 0.23 (±0.10, normal distribution, limit 0.53). FI increased with age and Estimated Post-Transplant Survival score. The FI was completed for 62.8% of eligible patients (147/234). The median completion time was 10 min, and completion rate (with no missing data) was 100%. Four themes were identified: perceptions of frailty, acceptability, perceived benefits, and risks of frailty measurement. Patients linked frailty with age and adverse outcomes, and most did not consider themselves frail. Patients reported that the FI was quick, simple, and efficient. They felt that frailty assessment is relevant to transplant eligibility and should be used to address potentially reversible factors. Conclusions. The FI demonstrated construct validity and was feasible and acceptable in this clinic setting. The challenge is ensuring that routine assessments lead to better care.
- Open Access
- 1 May 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (12) , 2454-2455
Should I Stay or Should I Go? The Role of Allograft Nephrectomy
- 1 May 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (12) , 2454-2455
Open AccessShould I Stay or Should I Go? The Role of Allograft Nephrectomy
- 30 June 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9) , 1732-1733
SGLT2i After Kidney Transplantation: Ready for Prime Time?
- 30 June 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9) , 1732-1733
SGLT2i After Kidney Transplantation: Ready for Prime Time?
- Open Access
- 3 March 2022
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 32 (6) , 718-725
Prebiotic Supplementation in Kidney Transplant Recipients for Preventing Infections and Gastrointestinal Upset: A Randomized Controlled Feasibility Study
- 3 March 2022
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 32 (6) , 718-725
Open AccessPrebiotic Supplementation in Kidney Transplant Recipients for Preventing Infections and Gastrointestinal Upset: A Randomized Controlled Feasibility Study
- Open Access
- 25 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0249000
Impact of deceased donor with acute kidney injury on subsequent kidney transplant outcomes–an ANZDATA registry analysis
Background: The need for kidney transplantation drives efforts to expand organ donation. The decision to accept organs from donors with acute kidney injury (AKI) can result in a clinical dilemma in the context of conflicting reports from published literature. Material and methods: This observational study included all deceased donor kidney transplants performed in Australia and New Zealand between 1997 and 2017. The association of donor-AKI, defined according to KDIGO criteria, with all-cause graft failure was evaluated by multivariable Cox regression. Secondary outcomes included death-censored graft failure, death, delayed graft function (DGF) and acute rejection. Results: The study included 10,101 recipients of kidneys from 5,774 deceased donors, of whom 1182 (12%) recipients received kidneys from 662 (11%) donors with AKI. There were 3,259 (32%) all-cause graft failures, which included 1,509 deaths with functioning graft. After adjustment for donor, recipient and transplant characteristics, donor AKI was not associated with all-cause graft failure (adjusted hazard ratio [HR] 1.11, 95% CI 0.99–1.26), death-censored graft failure (HR 1.09, 95% CI 0.92–1.28), death (HR 1.15, 95% CI 0.98–1.35) or graft failure when death was evaluated as a competing event (sub-distribution hazard ratio [sHR] 1.07, 95% CI 0.91–1.26). Donor AKI was not associated with acute rejection but was associated with DGF (adjusted odds ratio [OR] 2.27, 95% CI 1.92–2.68). Conclusion: Donor AKI stage was not associated with any kidney transplant outcome, except DGF. Use of kidneys with AKI for transplantation appears to be justified.
- 25 March 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (3) , e0249000
Open AccessImpact of deceased donor with acute kidney injury on subsequent kidney transplant outcomes–an ANZDATA registry analysis
Background: The need for kidney transplantation drives efforts to expand organ donation. The decision to accept organs from donors with acute kidney injury (AKI) can result in a clinical dilemma in the context of conflicting reports from published literature. Material and methods: This observational study included all deceased donor kidney transplants performed in Australia and New Zealand between 1997 and 2017. The association of donor-AKI, defined according to KDIGO criteria, with all-cause graft failure was evaluated by multivariable Cox regression. Secondary outcomes included death-censored graft failure, death, delayed graft function (DGF) and acute rejection. Results: The study included 10,101 recipients of kidneys from 5,774 deceased donors, of whom 1182 (12%) recipients received kidneys from 662 (11%) donors with AKI. There were 3,259 (32%) all-cause graft failures, which included 1,509 deaths with functioning graft. After adjustment for donor, recipient and transplant characteristics, donor AKI was not associated with all-cause graft failure (adjusted hazard ratio [HR] 1.11, 95% CI 0.99–1.26), death-censored graft failure (HR 1.09, 95% CI 0.92–1.28), death (HR 1.15, 95% CI 0.98–1.35) or graft failure when death was evaluated as a competing event (sub-distribution hazard ratio [sHR] 1.07, 95% CI 0.91–1.26). Donor AKI was not associated with acute rejection but was associated with DGF (adjusted odds ratio [OR] 2.27, 95% CI 1.92–2.68). Conclusion: Donor AKI stage was not associated with any kidney transplant outcome, except DGF. Use of kidneys with AKI for transplantation appears to be justified.